Compare Liberty Global Ltd Class C (LBTYK) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Liberty Global Ltd Class C vs Recursion Pharmaceuticals Inc — how do they compare? Liberty Global Ltd Class C trades at $8.52 (market cap $3.06B), while Recursion Pharmaceuticals Inc trades at $4.36 (market cap $2.14B). The key difference: Liberty Global Ltd Class C is the larger of the two by market cap, and Recursion Pharmaceuticals Inc is trading nearer its 52-week high, Liberty Global Ltd Class C nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Liberty Global Ltd Class C for 21 Days and Recursion Pharmaceuticals Inc for 23 Days on average.
| LBTYK | RXRX | |
|---|---|---|
Market Cap | $3.06B | $2.14B |
Volume | 2,508,956 | 30,789,535 |
Sector | Media | Health |
52-Week High | $12.67 | $6.79 |
52-Week Low | $8.52 | $2.84 |
Typical Hold Time | 21 Days | 23 Days |
Enterprise Value | $9.72B | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LBTYK trades at $8.75, near its 52-week low, reflecting a bearish technical trend with weak moving averages and oscillators. Fundamentally, the company reported a net loss of -$7.14B in 2025 despite $4.88B in revenue, though 2026 shows improvement with a reduced loss of -$3.0B. Recent strategic moves include the Ziggo Group spin-off preparation and an AI partnership to enhance customer experience.
The stock presents a high-risk opportunity with a discounted valuation (P/S 0.61, P/B 0.32) and strong analyst support (69% buy ratings, $12.67 target). Key risks are persistent losses and execution challenges, but upside potential exists if Ziggo's 2027 listing and cost controls drive profitability.
Recursion Pharmaceuticals (RXRX) trades at $3.95, down 7.49% today, with a mixed technical picture showing bullish moving averages but neutral oscillators. The company reported Q2 2026 earnings miss after two consecutive beats, while maintaining negative profitability metrics with a -961.97% net income margin. Recent strategic partnerships with Tempus and Roche aim to expand the AI-driven drug discovery pipeline through 2028.
RXRX presents high-risk growth potential with strong analyst support (40% buy rating) but faces substantial financial challenges including persistent losses and negative cash flow from operations. The stock's investment case hinges on successful pipeline development and partnership monetization, though current valuation appears stretched at 37.14x sales given the lack of profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Liberty Global Ltd Class C
Liberty Global is a world leader in converged broadband, video, and mobile communications. It operates large-scale fiber and 5G networks across Europe, providing essential digital services to millions of customers.
Read more on LBTYK →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
